ZIM Laboratories' Q4 financial results show a 7.63% year-over-year revenue decline to ₹1.09 billion. Despite this, the company improved its EBITDA margin to 13.42% from 13.28%. EBITDA slightly decreased to ₹146.00 million, while net profit fell significantly by 39.68% to ₹48.80 million compared to the same quarter last year. The results indicate challenges in revenue growth but demonstrate the company's focus on operational efficiency.
09Apr 25
ZIM Laboratories Expands into GCC Market with Globalpharma Partnership
ZIM Laboratories Limited, an Indian pharmaceutical company, has formed a strategic partnership with UAE-based Globalpharma Co. (L.L.C.) to introduce innovative oral thin film products in the Gulf Cooperation Council (GCC) region. The collaboration involves licensing ZIM's ThinOral® technology, registering 10 OTF-based products, and establishing a supply chain for localized manufacturing. This partnership aims to expand ZIM's presence in the Middle Eastern market while leveraging Globalpharma's regional footprint.